Peptide News Digest

CKYN GHK-Cu Skincare Launch June 20, JN GLP-1 Malnutrition Review June 20, Pfizer CFO Transition, Biogen Closes $5.6B Apellis Acquisition Adding Cyclic Peptide Pegcetacoplan, BIO 2026 Opens San Diego June 22

CKYN Complete GHK-Cu Protocol launch, JN GLP-1 malnutrition review, Pfizer CFO transition, Biogen completes $5.6B Apellis acquisition, BIO 2026 opens June 22.

5 stories · Covering industry, research

Editor's Note

Sunday rounds out a quiet weekend with two fresh Friday-Saturday items and three backdated stories not previously covered. CKYN LLC launched The Complete CKYN Protocol on June 20, a three-step GHK-Cu copper-tripeptide skincare system targeting the prestige consumer market with documented 22% firmness improvement and 16% fine-line reduction at 12 weeks — the latest move in the 2026 cosmetic-peptide industry buildout alongside Italgel avvera and GELITA CURADERM. The Journal of Nutrition's online-first June 20 review 'Avoiding malnutrition in the era of GLP-1 medications' frames an emerging clinical-care gap as 25% of GLP-1 weight loss is lean mass and calls for protein-intake standards, micronutrient monitoring, and routine body-composition (DXA/BIA) endpoints in late-stage GLP-1 trials. On the industry side, Pfizer announced June 18 that CFO Dave Denton departs August 15 with Cecile Guegan stepping in as interim — landing alongside Pfizer's berobenatide monthly GLP-1 Phase 2b detailed ADA data the same day and reaffirmed 2026 guidance of $59.5-62.5B. Two backdated stories: Biogen completed its $5.6B Apellis Pharmaceuticals acquisition May 14 after the May 13 tender offer closed at 82.4% participation — bringing pegcetacoplan (EMPAVELI/SYFOVRE), a pegylated cyclic peptide complement C3 inhibitor with $689M 2025 net revenue, into the Biogen growth portfolio. And BIO 2026 International Convention opens June 22-25 in San Diego with 20,000+ industry leaders across 130+ sessions, including the Insilico Medicine + SK Biopharmaceuticals $2.5B AI-driven neuroimmune drug discovery deal that will be announced opening day.

Industry

CKYN LLC Launches The Complete CKYN Protocol June 20: Three-Step GHK-Cu Copper Tripeptide Skincare System for Prestige Consumer Market — Documented 22% Firmness, 16% Fine-Line Reduction at 12 Weeks

CKYN LLC, a Kirkland, Washington-based skincare company, launched The Complete CKYN Protocol on June 20, 2026 — a three-step daily skincare system built entirely around GHK-Cu (Copper Tripeptide-1). The protocol comprises the Morning GHK-Cu Perfecting Lotion, Daytime GHK-Cu Tallow Balm, and Night-Time GHK-Cu Firming Serum. The product positioning anchors on six bioactives instead of the typical 20+ ingredient prestige skincare formulation, with concentrations targeted to clinical-study levels: published GHK-Cu research has shown 22% visibly firmer skin and 16% reduction in fine-line appearance after 12 weeks of consistent twice-daily application. GHK-Cu was first isolated from human plasma in 1973 by Dr. Loren Pickart and has accumulated four decades of cosmetic-science evidence. CKYN sits alongside Italgel avvera (June 12 launch) and GELITA CURADERM (Vitafoods Europe 2026) in the active 2026 cosmetic-peptide launch cycle.

#ckyn #ghk-cu #copper-peptide #cosmetic-peptides #skin-health #skincare-launch
Research

Journal of Nutrition Review (June 20): 'Avoiding Malnutrition in the Era of GLP-1 Medications' — 25% of GLP-1 Weight Loss is Lean Mass, Calls for Protein Standards and Routine Body-Composition Endpoints in Late-Stage Trials

The Journal of Nutrition published online on June 20, 2026 a review titled 'Avoiding malnutrition in the era of GLP-1 medications: emerging evidence and opportunities for integrated nutrition care.' The review documents that approximately 25% of total weight lost on GLP-1 therapy is lean mass — a substantial proportion depending on the magnitude of weight reduction achieved — and frames disproportionate fat-free mass loss as a metabolic-health and physical-function risk independent of total weight loss. The authors call for GLP-1-specific randomized trials defining optimal protein intake stratified by age, rate of weight loss, and baseline sarcopenia risk; guidance on when supplementation may be necessary; strategies for monitoring micronutrient status; and routine incorporation of body composition assessments (DXA/BIA) and standardized muscle function measures (handgrip strength, chair-rise testing) as co-primary or key secondary endpoints in future GLP-1 RA studies.

#glp-1-malnutrition #lean-mass-loss #nutrition-care #body-composition #dxa #clinical-endpoints #journal-of-nutrition
Industry

Pfizer CFO Dave Denton Transitions to Consumer Goods August 15; Cecile Guegan Named Interim CFO Effective August 16 — Pfizer Reaffirms 2026 Guidance of $59.5-62.5B Same-Day With Berobenatide Phase 2b ADA Detail

Pfizer announced on June 18, 2026 (8-K filed) that Chief Financial Officer Dave Denton will step down from his role and leave the company on August 15 for a professional opportunity outside the pharmaceutical industry in consumer goods. Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business (joined Pfizer in 2005, current role since 2022), was named Interim CFO effective August 16 while Pfizer conducts internal and external search. The same June 18 8-K reaffirmed 2026 guidance: revenues of $59.5-62.5B and adjusted diluted EPS of $2.80-3.00. Pfizer also presented detailed berobenatide (PF'3944) Phase 2b VESPER-1/-2/-3 data at the ADA Scientific Sessions June 6 supporting monthly dosing for the first-in-class GLP-1 RA peptide and confirmed plans for 10 Phase 3 studies in 2026 as part of a 20+ obesity-trial program. PFE stock dropped 3% on the CFO surprise.

#pfizer #cfo-transition #dave-denton #cecile-guegan #berobenatide #leadership-change
Industry

Biogen Completes $5.6B Apellis Pharmaceuticals Acquisition May 14, 2026 — Brings Cyclic Peptide Pegcetacoplan (EMPAVELI / SYFOVRE) With $689M 2025 Net Revenue Into the Growth Portfolio

Biogen (Nasdaq: BIIB) completed its $5.6B acquisition of Apellis Pharmaceuticals on May 14, 2026 after the May 13 tender offer closed at 82.4% of outstanding common stock at $41 per share in cash plus contingent value rights (up to $4 per share tied to SYFOVRE global net sales milestones). The transaction brings two commercialized peptide-based products into Biogen's portfolio: pegcetacoplan (EMPAVELI), a pegylated cyclic 13-amino-acid peptide complement C3 inhibitor approved for paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy / immune complex-membranoproliferative glomerulonephritis; and SYFOVRE, the intravitreal pegcetacoplan formulation for geographic atrophy secondary to age-related macular degeneration. Combined 2025 net product revenue was $689M. Biogen expects the deal to be Non-GAAP EPS accretive in 2027 and to materially increase Biogen's compound annual growth rate through end of decade. The deal restores a meaningful peptide-modality presence to Biogen's portfolio.

#biogen #apellis #pegcetacoplan #empaveli #syfovre #cyclic-peptide #ma-deal #complement-inhibitor
Industry

BIO 2026 International Convention Opens June 22-25 in San Diego With 20,000+ Industry Attendees, 130+ Sessions — Insilico-SK Biopharmaceuticals $2.5B AI Neuroimmune Drug Discovery Deal Set to Anchor Opening Day

The BIO International Convention opens Monday June 22 in San Diego through Thursday June 25, drawing 20,000+ industry leaders across 130+ sessions in 18 focus areas — the year's largest peptide-and-biopharma deal-making and pipeline conference. Among the opening-day announcements: Insilico Medicine and SK Biopharmaceuticals will formally announce a research and development collaboration to discover AI-enabled innovative drug candidates in the neuroimmune CNS area, with Insilico eligible for up to $18M in upfront and near-term milestone payments and total potential deal value exceeding $2.5B including development, regulatory, and commercial milestones plus single-digit royalties. The pact sets a record for Insilico's APAC partnership totals. Industry watchers will track BIO 2026's deal-making cadence as the post-ADA / post-ENDO cycle concludes and the FDA PCAC peptide-compounding decision (July 23-24) becomes the next major regulatory catalyst.

#bio-2026 #san-diego #biopharma-conference #insilico-medicine #sk-biopharmaceuticals #ai-drug-discovery #deal-making